Compare Citius Pharmaceuticals Inc (CTXR) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Keysight Technologies Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Keysight Technologies Inc trades at $324.37 (market cap $55.67B). The key difference: Keysight Technologies Inc is far larger — about 3802.6× Citius Pharmaceuticals Inc's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | KEYS | |
|---|---|---|
Market Cap | $14.64M | $55.67B |
Sector | Health | Technology |
52-Week High | $1.82 | $373.34 |
52-Week Low | $0.53 | $158.51 |
Enterprise Value | $10.86M | $56.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Keysight Technologies (KEYS) trades at $320.83, down 0.38% today, with technical indicators showing a bearish trend near key support at $317. The company reported strong Q1 2026 earnings of $2.87 per share, beating estimates of $2.32, and maintains robust profitability with a 17.31% net income margin. Recent news highlights product launches in network cybersecurity and photonics design, supporting growth in AI and 5G markets.
Wall Street maintains a bullish outlook with a $396.56 consensus price target and 75% buy ratings, though high valuation multiples and volatile cash flows pose risks. Upside potential hinges on execution in high-growth tech sectors, while investor sentiment is tempered by near-term technical weakness and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
